An analysis of the immunotherapy combination compared with sunitinib placed the combo on the high end of willingness-to-pay thresholds for cancer drugs.
Updated findings from a phase 3 study show significantly better 8-year progression-free survival with external beam radiation therapy added to androgen deprivation therapy (ADT) vs ADT alone.
Prostate mpMRI findings before and after neoadjuvant therapy prior to robotic prostatectomy could be useful in assessing whether high-risk patients are suitable surgical candidates.
Tumor diameter above the median was only significant predictor for positive MRI after treatment
Agency warns that rapid discontinuation can result in uncontrolled pain or withdrawal symptoms
New study finds that Vietnam War exposure to the defoliant Agent Orange is associated with a reduced death risk among men receiving androgen deprivation therapy for advanced prostate cancer.
Preventive drugs, including antihypertensives and statins, frequently continued until final month of life
Spero Therapeutics announced that the Food and Drug Administration (FDA) has granted Fast Track designation for SPR994 (tebipenem pivoxil hydrobromide) for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP)
Data support first-line treatment with combined regimens that include an immunotherapeutic agent
Biparametric MRI detects prostate tumors with an accuracy similar to that of multiparametric MRI without the cost and risks associated with intravenous gadolinium contrast, a new meta-analysis suggests.